Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

πŸ‡ΊπŸ‡Έ Seeking Alpha (US) —
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

AI Summary

Teva Pharmaceutical Industries announced Phase Ib 24-week efficacy results for an anti-IL-15 antibody treatment targeting vitiligo, with plans to advance to Phase 2b. This development reflects ongoing progress in clinical drug research within the pharmaceutical sector.

Markets Health Teva Pharmaceutical vitiligo clinical trials anti-IL-15 antibody Phase Ib results drug development

Read original source →